Registry study reveals delayed diagnosis, undertreatment, and elevated type 2 diabetes rates in familial hypercholesterolemia, highlighting the need for combination lipid-lowering therapies.
The results confirm late diagnosis, a lower than expected prevalence and risk of ASCVD, a higher than expected prevalence of type 2 diabetes and undertreatment, with relatively few patients reaching goals. Recommendations include, the use of combination lipid lowering therapy, control of comorbid conditions and more frequent genetic testing in the future.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: